2026-2034年全球癌症支持治療藥物市場規模、佔有率、趨勢和成長分析報告

預計癌症支持治療藥物的市場規模將從 2025 年的 257.9 億美元成長到 2034 年的 319 億美元，2026 年至 2034 年的複合年成長率為 2.39%。

隨著醫療專業人員致力於提高癌症患者的生活品質，全球癌症輔助治療藥物市場正在不斷擴大。這些藥物旨在控制化療、放射線治療和免疫療法等治療帶來的副作用，緩解疼痛、噁心、感染疾病和疲勞等症狀，幫助患者更好地耐受高強度的癌症治療。

多種因素正在推動癌症輔助治療藥物市場的擴張。全球癌症發生率的上升和先進治療方法的廣泛應用，都推動了對輔助治療藥物的需求。醫療保健系統日益重視全面的患者照護，既關注疾病管理，也關注治療相關的副作用。

隨著腫瘤學研究不斷開發出新的治療方法，預計市場將持續成長。製藥公司正投資研發創新輔助治療藥物，以改善病患的舒適度和治療效果。擴大癌症治療的覆蓋範圍和改善醫療基礎設施也有望促進該市場的長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球癌症支持治療藥物市場：按類型分類

• 市場分析、洞察與預測
• 促紅細胞生成素
• 顆粒細胞增生因子
• 止吐藥
• 雙磷酸鹽製劑
• 鴉片類藥物
• 非類固醇消炎劑
• 其他

第5章：全球癌症支持治療藥物市場：按應用領域分類

• 市場分析、洞察與預測
• 乳癌
• 肺癌
• 結腸癌
• 攝護腺癌
• 肝癌
• 胃癌
• 其他

第6章：全球癌症支持治療藥物市場：按分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 藥局和零售藥房
• 線上提供者

第7章 全球癌症支持治療藥物市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Baxter International Inc
  • Helsinn Healthcare SA
  • F. Hoffmann-La Roche AG
  • Pfizer Inc
  • Amgen Inc
  • Johnson & Johnson
  • Heron Therapeutics Inc
  • Merck & Co. Inc
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG

The Cancer Supportive Care Drugs Market size is expected to reach USD 31.90 Billion in 2034 from USD 25.79 Billion (2025) growing at a CAGR of 2.39% during 2026-2034.

The global cancer supportive care drugs market has grown as healthcare providers focus on improving the quality of life for patients undergoing cancer treatment. These drugs are designed to manage the side effects of therapies such as chemotherapy, radiation, and immunotherapy. They help alleviate symptoms such as pain, nausea, infections, and fatigue, enabling patients to better tolerate intensive cancer treatments.

Several factors are driving the expansion of the cancer supportive care drugs market. Increasing global cancer incidence and the growing use of advanced treatment methods have created greater demand for supportive medications. Healthcare systems are placing greater emphasis on comprehensive patient care that addresses both disease management and treatment-related side effects.

Looking forward, the market is expected to grow as oncology research continues to develop new treatment options. Pharmaceutical companies are investing in innovative supportive care drugs that enhance patient comfort and treatment outcomes. Expanding access to cancer care and improved healthcare infrastructure may also contribute to the long-term growth of this market.

MARKET SEGMENTATION

By Type

• Erythropoiesis Stimulating Agents
• Granulocyte Colony Stimulating Factors
• Antiemetics
• Bisphosphonates
• Opioids
• Nonsteroidal Anti Inflammatory Drugs
• Others

By Application

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Stomach Cancer
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers

COMPANIES PROFILED

• Baxter International Inc, Helsinn Healthcare SA, F HoffmannLa Roche AG, Pfizer Inc, Amgen Inc, Johnson Johnson, Heron Therapeutics Inc, Merck Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Erythropoiesis Stimulating Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Granulocyte Colony Stimulating Factors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Antiemetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Bisphosphonates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Opioids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Nonsteroidal Anti Inflammatory Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Stomach Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Drug Stores and Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Providers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER SUPPORTIVE CARE DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Baxter International Inc
  • 9.2.2 Helsinn Healthcare SA
  • 9.2.3 F. Hoffmann-La Roche AG
  • 9.2.4 Pfizer Inc
  • 9.2.5 Amgen Inc
  • 9.2.6 Johnson & Johnson
  • 9.2.7 Heron Therapeutics Inc
  • 9.2.8 Merck & Co. Inc
  • 9.2.9 Teva Pharmaceutical Industries Ltd
  • 9.2.10 Novartis AG